BAIT
BCL2L1
BCL-XL/S, BCL2L, BCLX, BCLXL, BCLXS, Bcl-X, PPP1R52, bcl-xL, bcl-xS, RP5-857M17.3
BCL2-like 1
GO Process (23)
GO Function (6)
GO Component (7)
Gene Ontology Biological Process
- apoptotic mitochondrial changes [TAS]
- apoptotic process [TAS]
- cytokinesis [IMP]
- extrinsic apoptotic signaling pathway in absence of ligand [IBA]
- innate immune response [TAS]
- intrinsic apoptotic signaling pathway [TAS]
- mitotic cell cycle checkpoint [IMP]
- negative regulation of anoikis [IMP]
- negative regulation of apoptotic process [IDA, IMP]
- negative regulation of autophagy [TAS]
- negative regulation of establishment of protein localization to plasma membrane [IDA]
- negative regulation of execution phase of apoptosis [IDA]
- negative regulation of extrinsic apoptotic signaling pathway in absence of ligand [TAS]
- negative regulation of intrinsic apoptotic signaling pathway [IDA]
- negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage [IDA]
- negative regulation of release of cytochrome c from mitochondria [IC, IDA]
- nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway [TAS]
- positive regulation of intrinsic apoptotic signaling pathway [TAS]
- regulation of mitochondrial membrane permeability [IDA]
- regulation of mitochondrial membrane potential [IDA]
- release of cytochrome c from mitochondria [IDA]
- response to cytokine [IDA]
- suppression by virus of host apoptotic process [IDA]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
PREY
SLC16A5
MCT5, MCT6
solute carrier family 16 (monocarboxylate transporter), member 5
GO Process (2)
GO Function (2)
GO Component (2)
Gene Ontology Biological Process
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
Negative Genetic
Mutations/deletions in separate genes, each of which alone causes a minimal phenotype, but when combined in the same cell results in a more severe fitness defect or lethality under a given condition. This term is reserved for high or low throughput studies with scores.
Publication
Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions.
Identification of effective combination therapies is critical to address the emergence of drug-resistant cancers, but direct screening of all possible drug combinations is infeasible. Here we introduce a CRISPR-based double knockout (CDKO) system that improves the efficiency of combinatorial genetic screening using an effective strategy for cloning and sequencing paired single guide RNA (sgRNA) libraries and a robust statistical scoring ... [more]
Nat. Biotechnol. Mar. 20, 2017; 0(); [Pubmed: 28319085]
Quantitative Score
- -4.18 [Confidence Score]
Throughput
- High Throughput
Ontology Terms
- phenotype: growth abnormality (HP:0001507)
Additional Notes
- CRISPR GI screen
- Cell Line:K562 (EFO:0002067)
- Experimental Setup:Timecourse
- GIST: A-phenotypic negative genetic interaction
- Library:Drug Target-CDKO CRISPRn library
- Significance Threshold: q-value<0.05
Curated By
- BioGRID